C-reactive protein as a prognostic indicator in COVID-19 patients

Mahmoud Sadeghi Haddad Zavareh
Masomeh Bayani
Mehran Shokri
Soheil Ebrahimpour
Arefeh Babazadeh
Zahra Geraili
Emaddudin Moudi
Ali Rostami
Mohammad Barari
Akram sadat Hosseini
Ali Bijani
Mostafa Javanian (✉ dr.javanian1@yahoo.com)

Research Article

Keywords: COVID-19; C-reactive protein; severity

DOI: https://doi.org/10.21203/rs.3.rs-307650/v1

License: © ️ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

While some biomolecules have been explored to identify potential biomarkers for prognosis of the COVID-19 prognosis, there are no reliable prognostic indicators of disease progression and severity. We aimed to evaluate the ability of the C-reactive protein (CRP) to predict COVID-19 infection.

This retrospective study was conducted on 429 patients diagnosed with COVID-19 between March 30, 2020, and April 30, 2020. The study population was divided into severe cases (n = 175) and nonsevere cases (n = 254). Data on demographic characteristics, clinical features, and laboratory findings on admission were collected.

The proportion of patients with increased CRP levels was significantly higher in severe cases than in nonsevere patients. Analysis of ROC curve found that CRP could be used as an independent factor in predicting the severity of COVID-19 infection. Also, patients with CRP > 64.75 mg/L were more likely to have severe complications.

The serum levels of CRP can predict the severity and progression of illness in patients with COVID-19.

Introduction

Since December 2019, a new type of coronavirus called coronavirus disease 2019 (COVID-19) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified in China [1]. The COVID-19 pandemic, then spread quickly around the world [2,3]. By August 16, 2020 there have been 21,294,845 confirmed cases of COVID-19, including 761,779 deaths, reported to the World Health Organization (WHO) [4]. The rapid spread of the SARS-CoV-2, rapid changes in clinical features and increased mortality have become the biggest problem in the world. Furthermore, there are no reliable prognostic indicators of disease progression. Recently, some studies have reported that C-reactive protein (CRP) levels can be used in the early diagnosis of pneumonia and that higher levels of CRP were associated with severe pneumonia [5]. Current research aims to evaluate CRP levels and disease progression in order to provide a reference for clinical management.

Materials And Methods

2.1. Study design, participants and definition

The present protocol of retrospective study has been approved by the Ethics Committee of Babol University of Medical Sciences, Babol, Iran (Code: IR.MUBABOL.REC.1399.041). The three affiliated hospitals at Babol University of Medical Sciences has been designed to treat patients with COVID-19. A total of adult 429 cases of COVID-19 were confirmed at these centers from March 30, 2020, to April 30, 2020. All patients with COVID-19 who enrolled in the recent study were diagnosed according to the WHO interim guidance for COVID-19 (6th edition) [6]. In other word, all patients with the physician- and laboratory-confirmed (positive in nasopharyngeal/throat swab specimens by reverse transcription polymerase chain reaction (RT-PCR)) COVID-19 infection were included, while suspected cases with similar clinical symptoms were excluded. All cases were monitored using the clinical data collected until March 30, 2020. One of the following criteria was used to determine severe COVID-19 illness: 1) respiratory rate ≥ 30 bpm; 2) oxygen saturation ≤ 93%; 3) arterial oxygen partial pressure (PaO2)/oxygen concentration (FiO2) ≤ 300 mmHg; 4) intensive care units (ICU) admission.

2.2. Data collection

Patient medical records were reviewed by an experienced team of clinicians of the Infectious Diseases Research Center of Babol University of Medical Sciences. The epidemiological, clinical, laboratory, radiological findings, and outcomes data
were collected using a data collection checklist from electronic medical records. Moreover, recorded patient data included demographic information, past medical history (PMH), underlying medical conditions, symptoms, and para-clinical data.

2.3. Statistical analysis

The statistical data was analyzed by using SPSS 16.0 (IBM, Chicago, IL, USA). Continuous and categorical variables were presented as median (IQR) and n (%), respectively. Mann-Whitney U test, \( \chi^2 \) test, or Fisher’s exact test was used to compare continuous and categorical variables.

The predictive value of the CRP was evaluated by measuring the area under the receiver operating characteristic curve (AUROC). The optimal threshold value was obtained by calculating the Youden index. A multivariate Cox proportional risk model was used to determine predictive factors for disease risk.

Results

There were 429 patients with COVID-19 in our study. Of these, 175 patients (40.8%) were assigned to a severe group, while 254 patients (59.2%) developed into non-severe cases. Demographic and clinical characteristics are summarized in Table 1. The mean age was 57.21±16.18 years with an age from 16 to 99 years. The average age was higher in the severe group compared with the non-sever group (p=0.111). One hundred and eighty-six (43.4%) were female. The severe ratio for males was higher than for females but this difference was not significant (p=0.122). The median duration from illness onset to discharge was 7 days. Overall, dyspnea (72.5%) was the most common initial symptom, followed by fever (61.3%), dry cough (57.6%). However, there was no significant difference in the symptoms ratio between the two groups.

Nearly, half of the patients (213, 49.7%) had comorbidities, diabetes (27.7%), cardiovascular disease (24.9%), hypertension (22.8%) were the most common comorbidities. Sixty two patients (14.5%) had a complication, including the occurrence of acute respiratory distress syndrome (ARDS) (18[10.3%] vs 0[0], P= 0.101), acute heart failure (9 [5.1%] vs 19 [7.5%], P= 0.335) and arrhythmia (8 [4.6%] vs 11 [4.3%], P= 0.905) (Table1). Laboratory findings for the patients are presented in Table2. Median levels of Lymphocyte percent, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and lactate dehydrogenase (LDH) were not in the normal range. Severe group had a significantly higher ESR ( MD: 57.5 vs MD: 40 , P=0.005) , CRP (MD: 97 vs MD: 50, p<0.001), LDH (MD: 783.5 vs MD: 459, p<0.001), and lower lymphocytes percent (MD: 12 vs MD: 22.7, p<0.001) compared to non-severe group.

Analysis of the ROC curve indicated an area under the curve (AUC) for CRP levels as a predictor of severity with 0.706 (95% CI, 0.649-0.764; p<0.001). The AUROC of this marker indicating a high diagnostic value for clinical severity and the optimal threshold value was 64.75 mg/L with a sensitivity of 71.32% and specificity of 60% (Table3 and Figure1). We reclassified patients into two groups according to the optimal CRP threshold (cut-off: 64.75). The proportion of severe patients with a CRP higher than the optimal threshold was significantly different compared to CRP lower than these values (p<0.001).

The univariate analysis used to logistic model indicated the severity was associated with hospital admission (OR, 1.166; 95% CI, 1.119-1.216; P=0.001), BUN (OR, 1.027; 95% CI, 1.014-1.040; P<0.001), lymphocyte (OR, 0.917; 95% CI, 0.895-0.939; P<0.001), and CRP (OR, 3.647 95% CI, 2.288-5.813; P<0.001). As determined by multivariate analysis, hospital admission (OR, 1.185; 95% CI, 1.086-1.293; P<0.001) and CRP (OR, 3.826; 95% CI, 1.166-12.560; P=0.027) were significantly associated with severity, the patients with CRP>64.75 were more likely to severity (Table4).

Discussion

In the present retrospective study, the clinical characteristics of severe COVID-19 patients have compared their clinical features with those of nonsevere patients and also analyzed the possible factors associated with disease progression and severity. Furthermore, the prognostic value of the CRP in the progression of COVID-19 cases has been revealed. The current study presented the association between CRP and COVID-19 infection and also found that cases with CRP > 64.75 mg/L
were more likely to develop severe disease. In other words, ROC analysis confirmed CRP as a valuable predictor of disease progression in COVID-19 infection.

In response to infections, the liver synthesizes great quantities of acute-phase proteins (APPs) such as CRP [7,8]. This acute inflammatory protein is a highly sensitive biomarker for inflammation, tissue damage, and infection [9]. It has been shown that CRP levels are correlated with levels of inflammation [10]. CRP levels can promote phagocytosis and activate the complement [11]. In other words, CRP binds to microorganisms and promotes their removal through phagocytic cells [12].

The serum CRP level is routinely low but increases during inflammatory responses. As shown, this biomarker may be raised by viral or bacterial infections. It is important to note, CRP levels have significantly increased in bacterial infections compared to viral infections [13]. The current study revealed that significantly higher CRP levels in severe cases than nonsevere patients, which suggested that CRP may be a biomarker of disease severity and progression in COVID-19 infection. Liu et al. reported that significantly more severe cases infected with COVID-19 experienced higher CRP levels versus non-severe patients [14]. Qin et al. presented that higher levels of CRP in severe COVID-19 patients compared to non-severe cases suggest that this serum marker may be monitored for evaluate disease progression [15]. As shown, all of these cases are similar to the results of the present study; CRP can be a predictive factor for disease progression in COVID-19. The limitations of the research were the small sample size and some limitations of the clinical data.

**Conclusion**

Serum CRP levels could be used as an important indicator of the severity of COVID-19 and also, the present study suggests that patients with high levels of CRP should be sufficiently monitored.

**Declarations**

**Competing interests**

The authors declare that they have no competing interests.

**Acknowledgments**

All of authors gratefully thank the department of infectious diseases of Babol University of Medical sciences, Iran.

**References**

1. JAVANIAN M, BAYANI M, SHOKRI M, et al. Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study. Rom J Intern Med. 2020;58:161-167.
2. HSIANG S, ALLEN D, ANNAN-PHAN S, et al. The effect of large-scale anti-contagion policies on the COVID-19 pandemic. Nature 2020;584:262-267.
3. MAS-COMA S, JONES MK, MARTY AM. COVID-19 and globalization. One Health 2020;9.
4. Organization WH. Coronavirus disease (COVID-19): situation report, 209. 2020.
5. LING W. C-reactive protein levels in the early stage of COVID-19. Med mal infect 2020; ;50:332-4.
6. XU X-W, WU X-X, JIANG X-G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. Bmj. 2020;368.
7. KHALIL RH, AL-HUMADI N. Types of acute phase reactants and their importance in vaccination. Biomed Rep. 2020;12:143-152.
8. KAMAL EM, ABD EL-HAKEEM MA, EL SAYED AM, AHMED MM. Validity of c-reactive protein and procalcitonin in prediction of bacterial infection in patients with liver cirrhosis. group;2:0.001.

9. SPROSTON NR, ASHWORTH JJ. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front Immunol 2018;9:754.

10. RAINER TH, CHAN CP, LEUNG MF, et al. Diagnostic utility of CRP to neopterin ratio in patients with acute respiratory tract infections. J Infect 2009;58:123-130.

11. GERSHOV D, KIM S, BROT N, ELKON KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000;192:1353-1364.

12. POVOA P, PEREIRA J, COELHO L, C-reactive protein: Structure, synthesis and function. C-Reactive Protein: New Research 2009:307-324.

13. COSTER D, WASSERMAN A, FISHER E, et al. Using the kinetics of C-reactive protein response to improve the differential diagnosis between acute bacterial and viral infections. Infection 2020;48:241-248.

14. LIU F, LI L, XU M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol 2020:104370.

15. QIN C, ZHOU L, HU Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020 ;71:762-768.

Tables

Table 1 Demographic data and baseline characteristics of patients infected with COVID-19
|                                | All patients (n=429) | Severe (n=175) | Non severe (n=254) | p-value |
|--------------------------------|----------------------|----------------|-------------------|---------|
| **Age, mean±SD** *(rang)*      | 57.21±16.18 (16-99)  | 58.75±15.88 (22-97) | 56.18±16.32 (16-99) | 1.59 | 0.111 |
| **Sex**                        | male                 | 241(56.4)       | 106(60.9)         | 135(53.4) | 2.39 | 0.122 |
|                                | female               | 186(43.6)       | 68(39.1)          | 118(46.6) |     |       |
| **Hospital admission(days)**   | 7(1-37)              | 10(1-37)        | 6(1-31)           | <0.001  |     |       |
| **Clinical symptoms**          |                      |                |                   |         |     |       |
| Fever                          | 263(61.3)            | 105(60)         | 158(62.2)         | 0.21    | 0.645 |
| Fatigue                        | 161(37.5)            | 70(40)          | 91(35.8)          | 0.77    | 0.380 |
| Headache                       | 76(17.7)             | 31(17.7)        | 45(17.7)          | 0.00    | 1.000 |
| Dry-Cough                      | 247(57.6)            | 98(56)          | 149(58.7)         | 0.003   | 0.584 |
| Sore Throat                    | 36(8.4)              | 19(10.9)        | 17(6.7)           | 2.33    | 0.126 |
| Expectorationn                 | 83(19.3)             | 34(19.4)        | 49(19.3)          | 0.001   | 0.972 |
| Hemoptysis                     | 7(1.6)               | 3(1.7)          | 4(1.6)            | 0.013   | 0.911 |
| Chest Pain                     | 61(14.2)             | 22(12.6)        | 39(15.4)          | 0.658   | 0.417 |
| Dyspnea                        | 311(72.5)            | 126(72)         | 69(72.8)          | 0.036   | 0.849 |
| Nausea                         | 81(18.9)             | 37(21.1)        | 44(17.3)          | 0.987   | 0.320 |
| Diarrhea                       | 25(5.8)              | 12(6.9)         | 13(5.1)           | 0.517   | 0.450 |
| Constipation                   | 24(5.6)              | 9(5.1)          | 15(5.9)           | 0.114   | 0.736 |
| Anorexia                       | 118(27.5)            | 53(30.3)        | 65(25.6)          | 1.14    | 0.284 |
| Arthralgia                     | 48(11.2)             | 20(11.4)        | 28(11)            | 0.017   | 0.896 |
| Stomachache                    | 39(9.1)              | 16(9.1)         | 23(9.1)           | 0.001   | 0.975 |
| Dizziness                      | 54(12.6)             | 21(12)          | 33(13)            | 0.093   | 0.761 |
| Loss of smell and taste        | 18(4.2)              | 9(5.1)          | 9(3.5)            | 0.659   | 0.417 |

**Comorbidity**

|                  | Hypertension | 98(22.8) | 32(18.3) | 66(26) | 3.48 | 0.062 |

Page 6/10
|                               | Severe | Nonsevere | Severe | Nonsevere | Severe | Nonsevere |
|-------------------------------|--------|-----------|--------|-----------|--------|-----------|
| Cardiovascular disease        |        |           |        |           |        |           |
|                               | 107(24.9) | 38(21.7) | 185(27.2) | 1.64 | 0.200 |
| Diabetes                      | 119(27.7) | 49(28) | 70(27.6) | 0.010 | 0.920 |
| Cancer                        | 10(2.3) | 3(1.7) | 7(2.8) | 0.494 | 0.482 |
| Chronic liver disease         | 5(1.2) | 3(1.7) | 2(0.8) | 0.773 | 0.379 |
| Chronic kidney disease        | 17(4) | 2(1.1) | 15(5.9) | 6.17 | 0.013 |
| Brain disease                 | 9(2.1) | 6(3.4) | 3(1.2) | 2.54 | 0.110 |
| COPD                          | 14(3.3) | 7(4) | 7(2.8) | 0.508 | 0.476 |
| Complication                  |        |           |        |           |        |           |
| Nosocomial pneumonia          | 8(1.9) | 2(1.1) | 6(2.4) | 0.842 | 0.359 |
| Urinary tract infections      | 6(1.4) | 2(1.1) | 4(1.6) | 0.140 | 0.708 |
| Shock                         | 5(1.2) | 5(2.8) | 0(0) | 3.22 | 0.073 |
| Acute heart failure           | 28(6.5) | 9(5.1) | 19(7.5) | 0.928 | 0.335 |
| Arrhythmia                    | 19(4.4) | 8(4.6) | 11(4.3) | 0.014 | 0.905 |
| ARDS                          | 18(4.2) | 18(10.3) | 0(0) | 2.68 | 0.101 |
| Acute kidney failure          | 1(0.4) | 0(0) | 1(0.4) | 0.691 | 0.406 |

: P values of the variables comparing severe and nonsevere patients are from t-test. Data are n (%) unless otherwise stated. **Abbreviation:** ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease
**Table 2** Laboratory findings of severe and non-severe COVID-19 cases

|                                | Normal range         | Severe (n=175)          | Non severe (n=254)        | P-value |
|--------------------------------|----------------------|-------------------------|---------------------------|---------|
| White blood cell count, median (range), cmm | 4500-11000 (1700-42300) | 9100 (2100-157000)       |                           | <0.001  |
| Lymphocytes %, median (range)   | 26-46 (2-36)         | 12 (2-36)               | 22.7 (3-75)               | <0.001  |
| Hemoglobin, median (range), (g/dL) | 13.5-18 (6-21)       | 11.95 (5.3-22.3)        | 12.5 (5.3-22.3)           | 0.032   |
| Erythrocyte sedimentation rate, median (range), mm/h | 0-15 (3-128)       | 57.5 (2-140)            | 40 (2-140)                | 0.005   |
| C-reactive protein, median (range), mg/L | 0-10 (1-440)       | 97 (1-440)              | 50 (4-392)                | <0.001  |
| Platelet count, median (range), mL | 140000-450000       | 197000 (42000-568000)   | 197000 (8000-1081000)     | 0.839   |
| Blood urea nitrogen, median (range), mg/dl | 10-20 (5-158.2)     | 19 (5-158.2)            | 15 (4-150)                | <0.001  |
| Creatinine, median (range), mg/dL | 0.7-1.4 (0.5-7.4)   | 1 (0.5-7.4)             | 1 (0.5-7.3)               | 0.360   |
| Lactate dehydrogenase, median (range), U/L | 140-280 (146-2436) | 783.5 (146-2436)        | 459 (30-2500)             | <0.001  |
| Sodium, median (range), mmol/L   | 135-145 (117-146)   | 135 (117-146)           | 136 (120-152)             | 0.144   |
| Potassium, median (range), mmol/L | 3.7-5.2 (3-8.2)     | 4.1 (2.9-5.5)           | 4.1 (2.9-5.5)             | 0.961   |

**Note:** P values of the variables comparing severe and nonsevere are from t-test. Data are n (%) unless otherwise stated.
Area under the ROC curve and optimal cut-off value of CRP

| AUC     | Optimal cut-off value | sensitivity | specificity | Predictive value | Likelihood ratio |
|---------|-----------------------|-------------|-------------|------------------|------------------|
| 0.706   | 64.75mg/L             | 71.32%      | 60%         | 78.11%           | 50.55%           | 0.48             | 1.76             |

Table 3
Table 4 Univariate and multivariate analyses used to logistic regression model

| Variable                  | Univariate | Multivariate |
|---------------------------|------------|--------------|
|                           | Odds Ratio (95% CI) | P-value | Odds Ratio (95% CI) | P-value |
| Age                       | 1.010 (0.998-1.022) | 0.112 | 1.003 (0.963-1.030) | 0.762 |
| Hospital admission (days) | 1.166 (1.119-1.216) | <0.001 | 1.185 (1.086-1.293) | <0.001 |
| lymphocyte                | 0.917 (0.895-0.939) | <0.001 | 0.990 (0.934-1.050) | 0.741 |
| BUN                       | 1.027 (1.014-1.040) | <0.001 | 1.045 (0.994-1.097) | 0.082 |
| Diabetes                  | 1.022 (0.665-1.571) | 0.920 | 2.543 (0.809-7.998) | 0.110 |
| CRP                       | 3.647 (2.288-5.813) | <0.001 | 3.826 (1.166-12.560) | 0.027 |

**Abbreviation:** ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; BUN, blood urea nitrogen; CRP, C-reactive protein; CI, confidence interval. *Statistically significant.